Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends

We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. MiMedx Group, Inc. is among the most undervalued stocks.

TheFly reported on April 20 that Citizens Financial Group lowered its price target on MDXG from $10 to $7 while maintaining an Outperform rating. The update noted that the company is pursuing significant expense reductions expected to cut annual operating costs by roughly $40 million. However, near-term performance remains under pressure due to slow recovery trends and ongoing reimbursement-related challenges in the wound care market, which continue to weigh on revenue growth. Despite these headwinds, the firm maintained a positive longer-term view, citing MDXG’s strong clinical evidence base, established operational network, and adaptability across evolving care environments.

Earlier on April 16, MiMedx Group, Inc. (NASDAQ:MDXG) announced a restructuring program aimed at lowering operating costs and focusing resources on growth priorities. The initiative is designed to streamline operations and improve efficiency across the business. As part of the changes, the company eliminated the Chief Operating Officer role, previously held by Ricci Whitlow.

Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends

The corporation’s Management indicated that further details regarding the restructuring and its financial impact would be shared alongside the first-quarter 2026 earnings discussion during the upcoming conference call later in April, where overall operating performance will also be addressed.

MiMedx Group, Inc. (NASDAQ:MDXG) is a regenerative medicine company specializing in placental biologics. It develops and markets human tissue-based products used for advanced wound care and surgical healing applications.

While we acknowledge the risk and potential of MDXG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDXG and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.